Indrabahadur Singh

Co-founder @Plexobio

Mannheim, DE
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Dec 2025 — Present

Co-founder @Plexobio

View department →

Mannheim, DE

Help to develop and commercialize preclinical models and biospecimen services2. Serve biotech clients seeking translational readiness in oncology drug development3. Help to build infrastructure for tissue access, model validation, and early-stage partnerships

EDUCATION

2007 — 2009

Indian Institute of Technology, Roorkee

Master's degree, Biotechnology

2011 — 2014

Justus Liebig University Giessen

Dr. Rer. Nat., Biochemistry, Genetics, Pulmonary Pharmacotherapy and Molecular Genetics

2015 — 2015

Pfeiffer University

Advanced Business Development

2004 — 2007

Ramniranjan Jhunjhunwala College (Autonomous)

Bachelor's degree, Biotechnology

2014 — 2016

Technische Hochschule Mittelhessen

MBA, Business Administration and Management, General

2015 — 2015

Università degli Studi di Bergamo

International Business

SKILLS

Protein PurificationEpigeneticsStrategic PartnershipsStrategic PlanningMolecular BiologyCoachingPolymerase Chain Reaction (Pcr)Reverse Transcription Polymerase Chain Reaction (Rt-Pcr)Rt-PcrReal-Time Polymerase Chain Reaction (Qpcr)ChipCancer ResearchProject ManagementCo-IpMouse ModelsWestern BlottingProtein ExpressionMammalian Cell CultureIn Vitro Chromatin ReconstitutionQpcrCell BiologyLung Fibrosis ResearchZebrafishPcrMolecular CloningScienceBiochemistryCell CultureBioinformaticsSouthern BlotTeam LeadershipTeam Management

ABOUT INDRABAHADUR SINGH

I’m a cancer biologist and translational researcher specializing in epigenetic mechanisms in cancer immunology and fibrosis. As Group Leader of the Ex-Emmy Noether Research Group “Epigenetic Machineries and Cancer” at the German Cancer Research Center (DKFZ), I led research on how chromatin regulators drive disease progression — and how we can target them.But throughout my academic journey, from a small village in India to one of Europe’s top research institutes, I’ve seen the same challenge play out:Scientific breakthroughs struggle to translate.Innovative targets, promising data, and early discoveries often get lost between academia and biotech — not due to lack of potential, but due to lack of structure, guidance, or access to the right tools.To address this, I founded: PlexoA GmbHA boutique service firm providing:1. Scientific & R&D due diligence2. Market & competitive landscape analysis3. Strategic Business & Development (BD) support for biotech, investors, and translational teams🧬 PlexoBio (early stage)A platform aim to offer AI and Blockchain powered:1. Custom preclinical models (oncology/fibrosis) access with pre-clinical and molecular data2. Human biospecimen access with clinical and molecular data3. Support for drug discovery, drug delivery, target validation and biomarker discoveryMy mission is simple:To bridge the gap between deep science and real-world impact. We make the inaccessible accessible. Open to:• SAB & advisory roles• R&D and BD collaborations• Sponsored research and partnershipsLet’s connect if you’re building something bold in epigenetics, oncology, tumor-immunology, fibrosis or translational science.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Indrabahadur Singh — Co-founder at Plexobio in Mannheim, DE | Unifers